Angle Share Discussion Threads

[purchaseatthetop] 19/1/2023 07:18

At last AN is bringing some heavyweights in with massive commercial experience

[mrkeysersoze] 19/1/2023 07:16

Very impressive CV Bones.....

Mr K.

[mrkeysersoze] 19/1/2023 07:15

Joseph Eid CV,

Roche was a company that AN referenced many times in the earlier days of Parsortix, interesting to see Eid was Clinical Science Leader at Roche.....


Experience

Luzsana Biotechnology
Luzsana Biotechnology

1 year 4 months
Chief Medical Officer I CMO I Spinout from Jiangsu Hengrui Pharmaceutical

Oct 2021 - Present1 year 4 months

Princeton, New Jersey, United States
Chief Medical Officer and Head, Global Drug Development

Oct 2021 - Present1 year 4 months

Princeton, New Jersey, United States

Board certified physician in Medical Oncology, Hematology, and Internal Medicine.
As Chief Medical Officer, Global Drug Development, I am responsible for developing and managing early and late-stage assets across all therapeutic areas.
I provide strategic and technical guidance for the company's portfolio development, as well as coordination, support and contribution to development activities, including Clinical Development, Clinical Operations, Monitoring, Pharmacovigilance230;

Bristol-Myers Squibb
Bristol-Myers Squibb

4 years

Senior Vice President and Head I SVP I Global Medical Affairs

Jun 2019 - Oct 20212 years 5 months

Member of the BMS Executive Leadership Team
Senior Vice President and Head I SVP I Global Medical Affairs

Nov 2017 - Oct 20214 years

Princeton Pike, New Jersey USA

Led a global organization responsible for supporting better health outcomes for patients and the safe and appropriate use of BMS Medicines through understanding the current and future needs of patients and medical care. The organization includes market based medical, HQ medical teams, and centers of excellence for collaborative science, medical information and publications.
Member of the BMS Early Development and Discovery Leadership Team
Member of the BMS Late Development Leadership…

Merck
Merck

8 years 7 months

Vice President and Head I VP I Oncology Global Medical Affairs

May 2014 - Oct 20173 years 6 months

Kenilworth, New Jersey USA

Led and built the Oncology Global Medical Affairs organization worldwide. This included the hiring of oncology personnel and the establishment of proper infrastructure and policies for all regional teams. In charge of the creation and management of OGMA strategy, Strategic Launch Plan and lifecycle strategy, evidence generation, scientific engagement and medical advisory activities. It also included direct interaction with international expert community, academic research groups, national…

Global Director of Scientific Affairs

Sep 2013 - May 20149 months

Whitehouse Station, New Jersey USA

In charge of the scientific engagement planning. Setting strategy for assets' research considerations, managing research budget, planning and chairing advisory board meetings and scientific input engagements. Chair of the oncology investigator initiated program. Oversaw an expansion and acceleration of the IIP program with review of over 700 proposals in the first year, with some research outcome leading to FDA approvals or providing POC for phase III programs.
Senior Project Leader

Mar 2011 - Sep 20132 years 7 months

Kenilworth, New Jersey USA

In charge of high priority and high visibility programs and managed multifunctional teams in charge of developing strategy and executing development plans for early and late-stage compounds.
Involved in numerous due diligence activities for in-licensing and out-licensing opportunities.
Responsible for the development of the global Keytruda® (Pembrolizumab, MK-3475) strategy including oversight of the clinical, regulatory and manufacturing planning and execution starting with first in man…

Section Head

Apr 2009 - Mar 20112 years

Upper Gwynedd, Pennsylvania USA

In charge of clinical research in global drug development with a spectrum of early and late stage clinical trials (Phase I, II, and III) in hematology/oncology areas including HDACi, mTORi, PARPi, AKTi, etc.
Managed a team of oncologists and scientists. Responsible for the strategic oversight of clinical development plans, approving studies’ designs and protocols. Managed personnel hiring and development. Member of the Senior Clinicians Group and the Oncology Licensing Committee.

Roche
Roche

5 years 1 month

Clinical Science Leader

Dec 2005 - Mar 20093 years 4 months

Nutley, New Jersey USA

In charge of clinical research in global drug development with a spectrum of early and late stage clinical trials (Phase I, II, and III) in hematology/oncology areas.
Managed a team of oncologists and scientists and member of the life cycle team. Responsible for the clinical development plan, approving studies’ designs and protocols.
Clinical Team Leader

Sep 2005 - Dec 20072 years 4 months

Nutley, New Jersey USA

Managed a matrix team responsible for the development of strategy and execution of clinical development plans for oncology products in phase 1-3.
Nutley Site Head for the Anemia Medical Team inclusive of oncology and renal teams.
Clinical Scientist

Mar 2004 - Dec 20051 year 10 months

Nutley, New Jersey USA

Clinical research in global drug development with focus on early and late-stage clinical trials (Phase I, II, and III) in hematology/oncology areas. Responsible for clinical research plan/study design, protocol writing including amendment and execution. Participated in advisory board meetings, SLs collaboration, central lab review/selection, site/investigator evaluation/approval, protocol training, investigator meetings, etc., and was member of the science medical team.

Rutgers Robert Wood Johnson Medical School
Rutgers Robert Wood Johnson Medical School

7 years 9 months

Assistant Professor

Jul 1999 - Mar 20044 years 9 months

New Brunswick, New Jersey USA

Maintained an active clinical practice one half day per week at Robert Wood Johnson Medical School through end of 2018.
Clinical staff on the medicine, hematology and bone marrow transplantation services.
Blood bank co-director.
Started and led as Medical Director the first regional comprehensive adult sickle cell center in New Jersey.
Member (1999-2004), and Chair (2002-2004), Sickle Cell Advisory Committee of the New Jersey Department of Health and Senior…

Clinical Instructor

Jul 1998 - Jun 19991 year

New Brunswick, New Jersey USA

Appointed to the faculty of RWJMS as Clinical Instructor at the start of my last year of fellowship.
Hematology/Oncology Fellow

Jul 1996 - Jun 19993 years

New Brunswick, New Jersey USA

Completed three years combined fellowship training in Hematology and Medical Oncology at the Cancer Institute of New Jersey.
Appointed chief fellow both in my second and third year of fellowship.

Staten Island University Hospital Graphic
Resident in Internal Medicine
Staten Island University Hospital

Jul 1993 - Jun 19963 years

Staten Island, New York USA

Completed three years training in Internal Medicine.

Mr K.

[bones698] 19/1/2023 07:14

Looks like a pretty impressive CV and big hitter finally . Let's hope he can make an impression

[kimchi1] 19/1/2023 07:10

Yes nice appointment

[mrmarmalade] 19/1/2023 07:09

A step in the right direction

[mrkeysersoze] 19/1/2023 07:09

Agrre patsym,

A great appointment added in todays RNS also early this month by Juliet Thompson.

It seems a new stratergy is in play with team Angle.......

" Joseph Eid M.D., commented:

"I believe that ANGLE's Parsortix technology and unique liquid biopsy approach has enormous potential both in oncology drug development and in the clinical setting. I look forward to leveraging my extensive experience of the development and use of biomarkers in oncology to drive forward the Company's strategy and to using my network of pharma industry, clinical and academic thought leaders to accelerate the Company's commercial development."

Mr K.

[bones698] 19/1/2023 07:09

plc ("the Company")

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Joseph Eid M.D., is a US certified medical oncologist with extensive experience of the use of biomarkers in clinical trials and as companion diagnostics

Previous roles include senior positions in oncology at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that Joseph (Joe) Eid M.D. has been appointed as a Non-Executive Director of the Company, with effect from 19 January 2023.

Joe is a qualified physician, board certified in medical oncology, haematology, and internal medicine. He is a highly experienced pharmaceutical industry executive with over 25 years of proven expertise in people and portfolio management, planning, designing, and executing Phase I to IV clinical trials and building and managing clinical and medical affairs teams and strategies. He has successfully designed and implemented clinical development, medical affairs, and life cycle management plans for pharmaceutical products including cytotoxic agents, monoclonal antibodies, immuno-oncology agents, antibody-drug conjugates, and CAR-T Cell therapies.

Joe most recently served as Chief Medical Officer and Head of Global Drug Development for Princeton, New Jersey based Luzsana Biotechnology (a wholly owned subsidiary of Jiangsu Hengrui Pharmaceutical). Importantly, his previous experience includes senior positions in clinical development and medical affairs at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche.

Whilst at Merck, Joe led the global Keytruda(R) (pembrolizumab, MK-3475) first-in-human strategy, including oversight of the clinical, regulatory, and manufacturing planning and execution and development of the PD-L1 biomarker strategy on tissue biopsy, which led to a first-in-class anti-PD-1 BLA filing and approval in the US

[patsym] 19/1/2023 07:04

Excellent news

[sicilian_kan] 19/1/2023 01:07

yasX, ARIX is a venture capital company that invests in bioscience. Half of its investment catalysts are at the preclinical level - not even in P1. It has no investments in a P3 project. It has more cash / NAV invested in private companies than it does in listed companies, which it cannot get out and which need further funding.

And you compare that to FDA approved Angle?

[joinednow] 19/1/2023 00:33

It may have potential just because of the IP regardless of sales.

Grail - few sales, but billions market value.

[bones698] 18/1/2023 20:58

Yes don't think they are done with TR1s yet . What will be interesting if anyone continues to add or was it just letting them in on the cheap .
That RNs was inexcusable tbh and a big two fingers to shareholders

[amaretto1] 18/1/2023 20:38

To let friends and family in ..... oh and your friendly hedge fund mates !!!Wait for another one to appear soon

[eeza] 18/1/2023 20:16

Yes, Avacta are focussed on commercialising their product and driving it forward, whilst Newland is focussed on Newland and his 'legacy'.

[amaretto1] 18/1/2023 20:15

Berenburg and Aegon have basically trashed the share price ......Were are the TR1s ??? It was a full on orchestrated bear raid on AGL .....To accommodate hedge funds taking positions......Imo AN was fully aware ... but this can't be proved .....The whole thing is verging on criminal

[amaretto1] 18/1/2023 20:11

Don't show how naive you are to the pharmaceutical sector ....Believe me .... Avacta is a very big risk at this valuation...... They have a phase 1 drug ... and a very very good PR company...It's high risk !!!! AGL have got the FDA ... the last RNS was a hatchet job .... they do not know actual 2023 figures ... how could they possibly know this ???

[amaretto1] 18/1/2023 19:53

It's 450 million valuation is insane !!!AGL is basically been shorted down to accommodate another fund to buy in ......AN imo is in the mix with them ...In other words they know the news flow time table ......It's all starting to look pretty odvious to anyone that understands mkt mechanics

[bones698] 18/1/2023 19:42

He seems to think time isn't an issue . I think the problem is more to do with the fact it won't be as easy as he thinks getting deals done and has focused pretty much in the USA which will be difficult at best . The recent RNs shows a pivot to lab testing and M&A but a bit late in the day trying to follow others lead . Avacta used M&A effectively . Lab testing will have been from the big bio companies ,they don't want a device that saves money etc just a way to bill patients for more money .

Interesting year hopefully but also not holding my breathe